Heron Therapeutics Inc vs SoundHound AI Inc — how do they compare? Heron Therapeutics Inc trades at $0.34 (market cap $61.47M), while SoundHound AI Inc trades at $7.32 (market cap $3.29B). The key difference: SoundHound AI Inc is far larger — about 53.5× Heron Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| HRTX | SOUN | |
|---|---|---|
Market Cap | $61.47M | $3.29B |
Sector | Health | Technology |
52-Week High | $1.49 | $21.40 |
52-Week Low | $0.32 | $5.70 |
Enterprise Value | $168.21M | $3.09B |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.
The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.
SOUN trades at $7.35, down 1.47% on the day, with a bullish technical signal from moving averages. The company reported strong revenue growth of 45% in Q2 2026 and raised its full-year outlook, driven by its OASYS platform. However, it remains unprofitable with a net income margin of -67.45% and negative cash flow from operations. Analyst sentiment is positive with a 75% buy rating and an $8.50 consensus price target.
The outlook hinges on SOUN's ability to convert rapid revenue growth into profitability. Investment opportunity lies in market leadership in voice AI and enterprise adoption via OASYS. Key risks include persistent cash burn, high valuation multiples, and execution challenges in integrating acquisitions like LivePerson.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →